Previous 10 | Next 10 |
Early data from Cohort 4 of the ongoing ZENITH20 clinical trial shows ORR of 44% in 48 first-line patients treated with 16mg of poziotinib once daily Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology thera...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small cell lung cancer (NSCLC) with HER2 exo...
Boston, Massachusetts--(Newsfile Corp. - September 1, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who purchased shares and have lost money are encourage...
BOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who have lost money in their Spectrum Pharmaceuticals investment should contact the firm to learn more abou...
Image source: The Motley Fool. Spectrum Pharmaceuticals, inc (NASDAQ: SPPI) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals, inc (SPPI) Q2 2021 Earnings Call Tr...
Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2021 Results Conference Call August 12, 2021 4:30 PM ET Company Participants Joe Turgeon – President and Chief Executive Officer Kurt Gustafson – Chief Financial Officer Francois Lebel – Chief Medical Officer Conference Call Partic...
Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS ® (eflapegrastim) Management ...
SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more. For further details see: Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity ...
Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...
Shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) were crashing 26.3% lower as of 11:14 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving canc...
News, Short Squeeze, Breakout and More Instantly...
Spectrum Pharmaceuticals Inc. Company Name:
SPPI Stock Symbol:
NASDAQ Market:
Spectrum Pharmaceuticals Inc. Website:
New York, New York--(Newsfile Corp. - December 14, 2022) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit. The lawsuit on behalf of Spectrum investors has been commenced in the the...
NEW YORK, NY / ACCESSWIRE / December 12, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) and reminds investors of the February 3, 2023 deadline to seek th...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 7, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...